148 related articles for article (PubMed ID: 15917654)
1. Li-Fraumeni syndrome: a p53 family affair.
Iwakuma T; Lozano G; Flores ER
Cell Cycle; 2005 Jul; 4(7):865-7. PubMed ID: 15917654
[TBL] [Abstract][Full Text] [Related]
2. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.
Lang GA; Iwakuma T; Suh YA; Liu G; Rao VA; Parant JM; Valentin-Vega YA; Terzian T; Caldwell LC; Strong LC; El-Naggar AK; Lozano G
Cell; 2004 Dec; 119(6):861-72. PubMed ID: 15607981
[TBL] [Abstract][Full Text] [Related]
3. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members.
Lomax ME; Barnes DM; Hupp TR; Picksley SM; Camplejohn RS
Oncogene; 1998 Aug; 17(5):643-9. PubMed ID: 9704930
[TBL] [Abstract][Full Text] [Related]
4. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
5. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T
Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations.
Xu J; Qian J; Hu Y; Wang J; Zhou X; Chen H; Fang JY
Sci Rep; 2014 Feb; 4():4223. PubMed ID: 24573247
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
Gu J; Kawai H; Wiederschain D; Yuan ZM
Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome.
Davison TS; Yin P; Nie E; Kay C; Arrowsmith CH
Oncogene; 1998 Aug; 17(5):651-6. PubMed ID: 9704931
[TBL] [Abstract][Full Text] [Related]
10. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
11. p53 expression in three separate tumours from a patient with Li-Fraumeni's syndrome.
King P; Craft AW; Malcolm AJ
J Clin Pathol; 1993 Jul; 46(7):676-7. PubMed ID: 8157761
[TBL] [Abstract][Full Text] [Related]
12. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.
Adhikari AS; Iwakuma T
Fukuoka Igaku Zasshi; 2009 Jun; 100(6):217-28. PubMed ID: 19670804
[TBL] [Abstract][Full Text] [Related]
14. Divergent control of Cav-1 expression in non-cancerous Li-Fraumeni syndrome and human cancer cell lines.
Sherif ZA; Sultan AS
Cancer Biol Ther; 2013 Jan; 14(1):29-38. PubMed ID: 23114650
[TBL] [Abstract][Full Text] [Related]
15. Complex replication error causes p53 mutation in a Li-Fraumeni family.
Strauss EA; Hosler MR; Herzog P; Salhany K; Louie R; Felix CA
Cancer Res; 1995 Aug; 55(15):3237-41. PubMed ID: 7614454
[TBL] [Abstract][Full Text] [Related]
16. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
17. Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements.
Kouidou S; Malousi A; Maglaveras N
Mol Carcinog; 2009 Oct; 48(10):895-902. PubMed ID: 19367569
[TBL] [Abstract][Full Text] [Related]
18. p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome.
Debelenko LV; Perez-Atayde AR; Dubois SG; Grier HE; Pai SY; Shamberger RC; Kozakewich HP
Pediatr Dev Pathol; 2010; 13(3):218-24. PubMed ID: 20028212
[TBL] [Abstract][Full Text] [Related]
19. The p53 mutation "gradient effect" and its clinical implications.
Zambetti GP
J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
[TBL] [Abstract][Full Text] [Related]
20. Multiple synchronous lung cancers and atypical adenomatous hyperplasia in Li-Fraumeni syndrome.
Nadav Y; Pastorino U; Nicholson AG
Histopathology; 1998 Jul; 33(1):52-4. PubMed ID: 9726049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
